JP7470683B2 - 新規な化合物およびカルシニューリン阻害剤を含む、移植拒絶反応または移植拒絶疾患を予防および治療するための組成物 - Google Patents

新規な化合物およびカルシニューリン阻害剤を含む、移植拒絶反応または移植拒絶疾患を予防および治療するための組成物 Download PDF

Info

Publication number
JP7470683B2
JP7470683B2 JP2021524277A JP2021524277A JP7470683B2 JP 7470683 B2 JP7470683 B2 JP 7470683B2 JP 2021524277 A JP2021524277 A JP 2021524277A JP 2021524277 A JP2021524277 A JP 2021524277A JP 7470683 B2 JP7470683 B2 JP 7470683B2
Authority
JP
Japan
Prior art keywords
cells
transplant rejection
combination
alone
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021524277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513590A5 (https=
JP2022513590A (ja
Inventor
チョ，ミラ
シン，ドンユン
チェ，ジョンヨン
ヤン，チョルウ
パク，ソンファン
イ，ソンヨン
パク，ミンジョン
チョン，ジュヨン
キム，セヨン
ソ，ヒョンボム
リュ，ジェユン
チョ，クンヒョン
Original Assignee
ザ カトリック ユニバーシティ オブ コリア インダストリー－アカデミック コーオペレイション ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ カトリック ユニバーシティ オブ コリア インダストリー－アカデミック コーオペレイション ファウンデーション filed Critical ザ カトリック ユニバーシティ オブ コリア インダストリー－アカデミック コーオペレイション ファウンデーション
Publication of JP2022513590A publication Critical patent/JP2022513590A/ja
Publication of JP2022513590A5 publication Critical patent/JP2022513590A5/ja
Application granted granted Critical
Publication of JP7470683B2 publication Critical patent/JP7470683B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021524277A 2018-11-07 2019-11-07 新規な化合物およびカルシニューリン阻害剤を含む、移植拒絶反応または移植拒絶疾患を予防および治療するための組成物 Active JP7470683B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020180136107A KR102147802B1 (ko) 2018-11-07 2018-11-07 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물
KR10-2018-0136107 2018-11-07
PCT/KR2019/015055 WO2020096371A1 (ko) 2018-11-07 2019-11-07 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물

Publications (3)

Publication Number Publication Date
JP2022513590A JP2022513590A (ja) 2022-02-09
JP2022513590A5 JP2022513590A5 (https=) 2022-10-20
JP7470683B2 true JP7470683B2 (ja) 2024-04-18

Family

ID=70612506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021524277A Active JP7470683B2 (ja) 2018-11-07 2019-11-07 新規な化合物およびカルシニューリン阻害剤を含む、移植拒絶反応または移植拒絶疾患を予防および治療するための組成物

Country Status (8)

Country Link
US (1) US11969397B2 (https=)
EP (1) EP3878443A4 (https=)
JP (1) JP7470683B2 (https=)
KR (1) KR102147802B1 (https=)
CN (1) CN113194936A (https=)
AU (1) AU2019377749B2 (https=)
CA (1) CA3118881A1 (https=)
WO (1) WO2020096371A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554139B2 (en) * 2019-05-17 2023-01-17 Tolerogenixx Gmbh MIC therapy for specific immunosuppression in transplantation
CN115843745A (zh) * 2021-09-26 2023-03-28 泰州迈博太科药业有限公司 一种人源化肠炎小鼠模型的构建方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510789A (ja) 2011-04-12 2014-05-01 ライジェル ファーマシューティカルズ， インコーポレイテッド 同種移植片拒絶反応を抑制する方法
JP2017519723A (ja) 2014-04-29 2017-07-20 ザ カトリック ユニバーシティ オブ コリア インダストリー−アカデミック コーオペレイション ファウンデーション 免疫疾患治療効果を有する新規化合物およびその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10369121B2 (en) 2013-08-23 2019-08-06 The Catholic University Of Korea Industry-Academic Cooperation Foundation Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient
WO2015167243A1 (ko) * 2014-04-29 2015-11-05 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
KR101613371B1 (ko) 2014-11-10 2016-04-18 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
KR101760510B1 (ko) 2014-12-18 2017-07-21 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
KR20180038355A (ko) 2016-10-06 2018-04-16 서울과학기술대학교 산학협력단 탄성 및 기계적 물성이 우수한 탄성 고분자-세라믹 하이브리드 필름 및 이의 제조방법
KR20190045513A (ko) 2017-10-24 2019-05-03 가톨릭대학교 산학협력단 Sd282 화합물 또는 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 후 면역 질환의 예방 및 치료용 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510789A (ja) 2011-04-12 2014-05-01 ライジェル ファーマシューティカルズ， インコーポレイテッド 同種移植片拒絶反応を抑制する方法
JP2017519723A (ja) 2014-04-29 2017-07-20 ザ カトリック ユニバーシティ オブ コリア インダストリー−アカデミック コーオペレイション ファウンデーション 免疫疾患治療効果を有する新規化合物およびその使用

Also Published As

Publication number Publication date
US20220031637A1 (en) 2022-02-03
EP3878443A4 (en) 2022-08-24
WO2020096371A1 (ko) 2020-05-14
US11969397B2 (en) 2024-04-30
EP3878443A1 (en) 2021-09-15
AU2019377749B2 (en) 2024-10-03
AU2019377749A2 (en) 2021-06-03
CN113194936A (zh) 2021-07-30
CA3118881A1 (en) 2020-05-14
KR102147802B1 (ko) 2020-08-25
KR20200052743A (ko) 2020-05-15
JP2022513590A (ja) 2022-02-09
AU2019377749A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
Gazdic et al. Crosstalk between mesenchymal stem cells and T regulatory cells is crucially important for the attenuation of acute liver injury
US11793865B2 (en) Cultured phagocyte supernatent compositions
KR101941004B1 (ko) 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물
US20080305079A1 (en) Myeloid Suppressor Cells, Methods For Preparing Them, and Methods For Using Them For Treating Autoimmunity
Lopez‐Santalla et al. Adipose‐derived mesenchymal stromal cells modulate experimental autoimmune arthritis by inducing an early regulatory innate cell signature
KR20110018273A (ko) 염증 예방 또는 치료용 조성물
JP7470683B2 (ja) 新規な化合物およびカルシニューリン阻害剤を含む、移植拒絶反応または移植拒絶疾患を予防および治療するための組成物
JP2014506896A (ja) アミノチアゾールｍｙｄ８８特異的阻害剤の薬学的な使用
Li et al. The protection and therapy effects of bortezomib in murine acute graft-versus-host disease
KR20130106786A (ko) 골수유래억제세포 및 레바미피드를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
KR101694554B1 (ko) 자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물
CA2648889C (en) Use of thymosin alpha 1 for the treatment of immunological diseases
KR20120026208A (ko) Ｓｔａ-21을 유효성분으로 함유하는 암 또는 면역질환의 예방 및 치료용 조성물
WO2005055920A2 (en) Compositions and methods for treatment of psychiatric disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210708

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221012

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240408

R150 Certificate of patent or registration of utility model

Ref document number: 7470683

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150